Media stories about Imprimis Pharmaceuticals (NASDAQ:IMMY) have trended somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 50 out of 100, indicating that recent media coverage is somewhat likely to have an impact on the stock’s share price in the next few days.

A number of research firms recently issued reports on IMMY. Zacks Investment Research upgraded shares of Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. ValuEngine cut shares of Imprimis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 16th.

Shares of Imprimis Pharmaceuticals (NASDAQ IMMY) traded down 8.59% during trading on Monday, reaching $2.66. 190,235 shares of the company traded hands. Imprimis Pharmaceuticals has a 52 week low of $1.65 and a 52 week high of $4.69. The company’s market capitalization is $53.37 million. The company’s 50-day moving average price is $3.24 and its 200-day moving average price is $3.15.

Imprimis Pharmaceuticals (NASDAQ:IMMY) last released its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.07. The firm had revenue of $6.10 million during the quarter, compared to analysts’ expectations of $6.50 million. Imprimis Pharmaceuticals had a negative return on equity of 388.64% and a negative net margin of 90.48%. Equities research analysts forecast that Imprimis Pharmaceuticals will post ($0.86) EPS for the current fiscal year.

In other Imprimis Pharmaceuticals news, Director Robert J. Kammer sold 10,000 shares of the stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $3.05, for a total transaction of $30,500.00. Following the completion of the sale, the director now directly owns 1,059,827 shares of the company’s stock, valued at approximately $3,232,472.35. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 12.55% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/07/24/imprimis-pharmaceuticals-immy-receiving-somewhat-favorable-press-coverage-study-shows-updated.html.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.

Insider Buying and Selling by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Receive News & Stock Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.